Notice

This is not the latest version of this item. The latest version can be found at: https://directory.doabooks.org/handle/20.500.12854/81838.2

Show simple item record

dc.contributor.editorBott, Simon RJ
dc.contributor.editorNg, Keng Lim
dc.date.accessioned2022-05-22T00:48:51Z
dc.date.available2022-05-22T00:48:51Z
dc.date.issued2021-05-27
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/81838
dc.description.abstractProstate cancer is a life-altering diagnosis, not just for patients, but for their loved ones as well. Once, prostate cancer was most frequently diagnosed in men in their 60s and 70s; with increasing use of imaging modalities and PSA testing, the incidence is on the rise, and we are now seeing men in their 40s with the disease. This poses a challenge for clinical management depending on the stage of the disease—from watchful waiting or active surveillance to aggressive treatment with the risk of therapeutic nihilism. Despite being one of the most common cancers in Western men, its natural history, prognosis, and treatment are poorly understood. This book brings together a select faculty of experts to present a comprehensive view of the current state and future perspectives of prostate cancer. There are ten chapters in the book—the first four cover our present knowledge and understanding of the disease, the following three explore new advancements and treatments, particularly looking at overcoming resistance to therapy, and the remaining three chapters focus on specific molecules with the potential to become drug targets. We all have much to learn about prostate cancer. This book is aimed primarily at clinicians and scientists, but many areas will also be of interest to the layperson.en_US
dc.languageEnglishen_US
dc.subject.classificationMJSen_US
dc.subject.otherEpidemiology of Prostate Cancer; Etiology of Prostate Cancer; Pathogenesis of Prostate Cancer; Current Diagnostics for Prostate Cancer; Combination Treatment for Prostate Cancer; Castration-Resistant Prostate Cancer; Theranostics in Metastatic Castrate Resistant Prostate Cancer; Adenocarcinoma of the Prostate; p53 in Prostate Cancer; MUCIN 1 in Prostate Cancer; STEAP Proteins in Prostate Canceren_US
dc.titleProstate Canceren_US
dc.typebook
dc.description.versionPublisheden_US
oapen.identifier.doi10.36255/exonpublications.prostatecancer.2021en_US
oapen.relation.isPublishedBy2d6001a3-9e06-4979-bf02-6974e313eb24
oapen.relation.isbn9780645001754en_US
oapen.pages157en_US
oapen.place.publicationAustraliaen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
VersionItemDateSummary

*Selected version